Clinical trials: Neuroblastoma
Neuroblastoma
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
- Trial name
- NCT04724369
- Testing
- 18F-MFBG
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Neuroblastoma, Diffuse Intrinsic Pontine Glioma
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in…
- Trial name
- PEACH (NCT04837547)
- Testing
- Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Neuroblastoma
Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in childhood, with nearly 50% of patients presenting with widespread metastatic disease.
- Trial name
- NCT01857934
- Testing
- cyclophosphamide, topotecan, hu14.18K322A
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- St. Jude Children's Research Hospital
Neuroblastoma
A Prospective Image Reevaluation Study to Assess the Efficacy of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
This is a prospective image revaluation study designed to assess the performance of 18F-mFBG PET imaging in detecting the presence of neuroblastoma.
- Trial name
- 101-305 (NCT07833631)
- Testing
- 18F-MFBG
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03698994
- Testing
- Pharmacokinetic Study, Ulixertinib
- Where
- 107 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Rapid Administration Pilot for Infusing Dinutuximab
Dinutuximab is an immunotherapy that has greatly improved outcomes for children with high-risk neuroblastoma and is now a standard part of treatment for both newly diagnosed and relapsed disease.
- Trial name
- RAPID (NCT05421897)
- Testing
- Dinutuximab with Chemotherapy
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Los Angeles
High-Risk Neuroblastoma
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
This clinical trial will evaluate the safety of chemoimmunotherapy with Naxitamab and COG-type induction chemotherapy in newly-diagnosed patients with high-risk neuroblastoma. We aim to recruit 10 patients over the next 2 years.
- Trial name
- NCT07537400
- Testing
- Naxitamab
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Shaare Zedek Medical Center
Relapsed Neuroblastoma, Refractory Neuroblastoma
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and tolerability of universal donor TGFβi NK Cell in combination with irinotecan, temozolomide, and dinituximab.
- Trial name
- STING (NCT04211675)
- Testing
- Natural Killer Cells, Temozolomide, Irinotecan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Nationwide Children's Hospital
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular
Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma
This phase II trial evaluates whether an investigational scan (18F-MFBG positron emission tomography [PET]/computed tomography [CT] or PET/magnetic resonance imaging [MRI]) can accurately detect tumors in patients with newly…
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, High Risk Neuroblastoma
- Trial name
- NCT06858501
- Testing
- Biospecimen Collection, Computed Tomography, Florbenguane F18
- Sponsor
- Children's Oncology Group
Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
This phase I/II trial tests the safety, side effects, best dose and how well giving daraxonrasib works for the treatment of pediatric patients with solid tumors with RAS mutations that has come back after a period of improvement…
- Conditions
- Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma, Refractory Childhood Malignant Solid Neoplasm
- Trial name
- NCT07819838
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Volunteers
- 77 people
- Sponsor
- Children's Oncology Group
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital
Pediatric Cancer, Neuroblastoma
Biomarkers of Resiliency In Childhood Cancer Surgery
This observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can create ways to improve resilience during recovery.
- Conditions
- Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors
- Trial name
- BRICCS (NCT06674811)
- Testing
- Wearing Smartwatch, Patient Report Outcomes, Blood Draw
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Neuroblastoma
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
The survival rate of recurrent and refractory neuroblastoma is low and the prognosis is poor. Apatinib mesylate is a highly selective small-molecule vasoendothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor.
- Trial name
- NCT05027386
- Testing
- Apatinib, Irinotecan, Temozolomide
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Sun Yat-sen University
Recurrent Neuroblastoma, Refractory Neuroblastoma
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma that does not respond to treatment or…
- Trial name
- NCT01711554
- Testing
- Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis
- Where
- 15 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard…
- Trial name
- PEDS-PLAN (NCT02559778)
- Testing
- Ceritinib, dasatinib, sorafenib
- Where
- 28 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Giselle Sholler
Neuroblastoma
Neuroblastoma Maintenance Therapy Trial
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission.
- Trial name
- NMTT (NCT02679144)
- Testing
- Difluoromethylornithine (DFMO)
- Where
- 47 sites in United States, Canada
- Volunteers
- 441 people
- Sponsor
- Giselle Sholler
Congenital Central Hypoventilation Syndrome
International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
The Center for Autonomic Medicine in Pediatrics (CAMP), in collaboration with leading CCHS clinicians, scientists, and patient advocacy groups around the world has built the first International CCHS (Congenital Central…
- Trial name
- NCT03088020
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Ilya Khaytin
Congenital Central Hypoventilation Syndrome, Congenital Central Hypoventilation
Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS)
Congenital central hypoventilation syndrome (CCHS) is a rare disorder of autonomic and respiratory regulation that frequently alters oxygen delivery to the brain.
- Conditions
- Congenital Central Hypoventilation Syndrome, Congenital Central Hypoventilation, CCHS, CCHS With Hirschsprung Disease
- Trial name
- NCT03568669
- Testing
- NIH Toolbox Cognition Battery
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Ilya Khaytin
Neuroblastoma
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
- Trial name
- NCT04301843
- Testing
- Eflornithine
- Where
- 29 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Giselle Sholler